LOW MOLECULAR WEIGHT HEPARIN IN TREATMENT OUTCOME OVER SEVERITY OF ACUTE PANCREATITIS

Abstract

Introduction: Acute pancreatitis, a multifactorial disease, prompts various etiologies. Low Molecular Weight Heparin (LMWH) emerges as a potential intervention due to its ability to reduce cytokine release, inflammatory mediators, and inhibit trypsin activity. These actions, beyond its anticoagulant properties, contribute to improving pancreatic microcirculation and mitigating adverse outcomes in acute pancreatitis (AP).The aim is to investigate the impact of LMWH on the outcome of moderately severe and severe acute pancreatitis.

Materials and Methods: The study included 50 patients over a 6-month period (July 2023 - December 2023), with 35 in Group A (standard treatment) and 15 in Group B (LMWH treatment). Statistical analysis employed SPSS 24, with a significance level set at P < 0.001.

Results:

• Patient Demographics: Majority male patients (92%) aged 26-55.


• Heparin Administration: 30% received LMWH.


• APACHE Scores:
  
  
  
  • Admission: Similar in both groups (p = 0.524).
  
  
  • Day 7: LMWH group significantly decreased compared to the non-LMWH group (p = 0.001).
  
  
  
  


• Outcome: 100% recovery in both groups.

Discussion: Early pancreatitis stages crucially impact outcomes, with microcirculation impairment being a pivotal factor leading to necrosis. A study comparing LMWH addition to conventional treatment showcased significant improvements in laboratory indices, a higher cure rate, and lower complication incidence. The decline in APACHE-II scores in the LMWH-treated group was notably larger, emphasizing its potential in reducing inflammation and complications.

Conclusion: LMWH augmentation in conventional treatment for acute pancreatitis demonstrated enhanced efficacy and a substantial reduction in mortality. LMWH stands out as a simple, safe, economical, and effective intervention for acute pancreatitis.